Literature DB >> 12819464

Tumor necrosis factor biology in experimental and clinical arthritis.

Petros P Sfikakis1, George Kollias.   

Abstract

The successful introduction of antitumor necrosis factor treatments in clinical practice confirmed the biologic relevance of tumor necrosis factor function in chronic inflammatory conditions in humans, mainly in the pathogenesis of rheumatoid arthritis and inflammatory bowel disease. Studies on patients receiving antitumor necrosis factor treatments offered deeper insights into the mechanisms of antitumor necrosis factor action in arthritis and revealed a master regulatory role for tumor necrosis factor in a multitude of biologic processes underlying pathogenesis. However, within such pleiotropism of key functions, blockade of tumor necrosis factor has also led to a significant incidence of unwanted clinical complications. Experimental work in animal models is providing additional clues on the specific function of tumor necrosis factor and its receptors in disease, especially on the molecular and cellular pathways through which tumor necrosis factor orchestrates beneficial and deleterious responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819464     DOI: 10.1097/00002281-200307000-00003

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  11 in total

Review 1.  Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature.

Authors:  V Wiegering; H Morbach; A Dick; H J Girschick
Journal:  Rheumatol Int       Date:  2009-06-09       Impact factor: 2.631

Review 2.  Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders.

Authors:  Isabel Pascual-Camps; Pablo Hernández-Martínez; Laura Monje-Fernández; Rosa Dolz-Marco; Roberto Gallego-Pinazo; Lihteh Wu; J Fernando Arévalo; Manuel Díaz-Llopis
Journal:  J Ophthalmic Inflamm Infect       Date:  2014-10-15

Review 3.  Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review.

Authors:  Eleftherios Pelechas; Alexandra Papoudou-Bai; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Rheumatol Int       Date:  2018-12-07       Impact factor: 2.631

4.  Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis.

Authors:  Irene Pontikaki; Edit Shahi; Lucretia Adina Frasin; Raffaele Gianotti; Carlo Gelmetti; Valeria Gerloni; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

5.  [First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept].

Authors:  S Boms; T Sehr; U Jappe; A Enk
Journal:  Hautarzt       Date:  2008-08       Impact factor: 0.751

Review 6.  Diabetic macular edema: New promising therapies.

Authors:  Hanan N Al Shamsi; Jluwi S Masaud; Nicola G Ghazi
Journal:  World J Diabetes       Date:  2013-12-15

7.  Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism.

Authors:  Zhenqiang Yao; Lianping Xing; Chunlin Qin; Edward M Schwarz; Brendan F Boyce
Journal:  J Biol Chem       Date:  2008-02-04       Impact factor: 5.157

8.  Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols.

Authors:  Eleni Douni; Petros P Sfikakis; Sylva Haralambous; Peter Fernandes; George Kollias
Journal:  Arthritis Res Ther       Date:  2003-11-07       Impact factor: 5.156

9.  An anti-TNF-α antibody mimetic to treat ocular inflammation.

Authors:  Hanieh Khalili; Richard W Lee; Peng T Khaw; Steve Brocchini; Andrew D Dick; David A Copland
Journal:  Sci Rep       Date:  2016-11-22       Impact factor: 4.379

10.  An unusual case of Behcet disease with posterior scleritis: A case report.

Authors:  Chihiro Yanagida; Yoshihiko Usui; Jun-Ichi Sakai; Hiroshi Goto
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.